Home/Filings/4/0000950170-25-002102
4//SEC Filing

Janku Filip 4

Accession 0000950170-25-002102

CIK 0001826457other

Filed

Jan 5, 7:00 PM ET

Accepted

Jan 6, 4:15 PM ET

Size

7.5 KB

Accession

0000950170-25-002102

Insider Transaction Report

Form 4
Period: 2025-01-02
Janku Filip
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-01-02+161,000161,000 total
    Exercise: $7.11Exp: 2035-01-01Common Stock (161,000 underlying)
  • Award

    Common Stock

    2025-01-02+36,00045,189 total
Footnotes (3)
  • [F1]Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
  • [F2]Includes 3,937 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 28, 2024.
  • [F3]25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Documents

1 file

Issuer

Monte Rosa Therapeutics, Inc.

CIK 0001826457

Entity typeother

Related Parties

1
  • filerCIK 0001862930

Filing Metadata

Form type
4
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 4:15 PM ET
Size
7.5 KB